These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 11436350)

  • 21. Transgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions.
    Bates GP; Davies SW
    Mol Med Today; 1997 Nov; 3(11):508-15. PubMed ID: 9430787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein.
    Jiang H; Nucifora FC; Ross CA; DeFranco DB
    Hum Mol Genet; 2003 Jan; 12(1):1-12. PubMed ID: 12490527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Surface plasmon resonance characterization of specific binding of polyglutamine aggregation inhibitors to the expanded polyglutamine stretch.
    Okamoto Y; Nagai Y; Fujikake N; Akiko Popiel H; Yoshioka T; Toda T; Inui T
    Biochem Biophys Res Commun; 2009 Jan; 378(3):634-9. PubMed ID: 19061859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trinucleotide repeats and neurodegenerative disease.
    Everett CM; Wood NW
    Brain; 2004 Nov; 127(Pt 11):2385-405. PubMed ID: 15329351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapeutic strategies for the polyglutamine diseases].
    Nagai Y; Popiel HA; Fujikake N; Toda T
    Brain Nerve; 2007 Apr; 59(4):393-404. PubMed ID: 17447526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polyglutamine diseases: a transcription disorder?
    Okazawa H
    Cell Mol Life Sci; 2003 Jul; 60(7):1427-39. PubMed ID: 12943229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allele-selective suppression of mutant genes in polyglutamine diseases.
    Liu CR; Cheng TH
    J Neurogenet; 2015; 29(2-3):41-9. PubMed ID: 26174158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of ter94, Drosophila VCP, as a modulator of polyglutamine-induced neurodegeneration.
    Higashiyama H; Hirose F; Yamaguchi M; Inoue YH; Fujikake N; Matsukage A; Kakizuka A
    Cell Death Differ; 2002 Mar; 9(3):264-73. PubMed ID: 11859409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analyzing the aggregation of polyglutamine-expansion proteins and its modulation by molecular chaperones.
    Kubota H; Kitamura A; Nagata K
    Methods; 2011 Mar; 53(3):267-74. PubMed ID: 21195182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila.
    Nagai Y; Fujikake N; Ohno K; Higashiyama H; Popiel HA; Rahadian J; Yamaguchi M; Strittmatter WJ; Burke JR; Toda T
    Hum Mol Genet; 2003 Jun; 12(11):1253-9. PubMed ID: 12761040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation.
    Schaffar G; Breuer P; Boteva R; Behrends C; Tzvetkov N; Strippel N; Sakahira H; Siegers K; Hayer-Hartl M; Hartl FU
    Mol Cell; 2004 Jul; 15(1):95-105. PubMed ID: 15225551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of inter-locus polyglutamine toxicity with CAG•CTG triplet repeat expandability and flanking genomic DNA GC content.
    Nestor CE; Monckton DG
    PLoS One; 2011; 6(12):e28260. PubMed ID: 22163004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perturbation of U2AF65/NXF1-mediated RNA nuclear export enhances RNA toxicity in polyQ diseases.
    Tsoi H; Lau CK; Lau KF; Chan HY
    Hum Mol Genet; 2011 Oct; 20(19):3787-97. PubMed ID: 21725067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expanded polyglutamine stretches form an 'aggresome'.
    Shimohata T; Sato A; Burke JR; Strittmatter WJ; Tsuji S; Onodera O
    Neurosci Lett; 2002 May; 323(3):215-8. PubMed ID: 11959423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polyglutamine expansion diseases: failing to deliver.
    Morfini G; Pigino G; Brady ST
    Trends Mol Med; 2005 Feb; 11(2):64-70. PubMed ID: 15694868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
    Nagai Y; Popiel HA
    Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caspases that are activated during generation of nuclear polyglutamine aggregates are necessary for DNA fragmentation but not sufficient for cell death.
    Kouroku Y; Fujita E; Urase K; Tsuru T; Setsuie R; Kikuchi T; Yagi Y; Momoi MY; Momoi T
    J Neurosci Res; 2000 Nov; 62(4):547-56. PubMed ID: 11070498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polyglutamine expansion reduces the association of TATA-binding protein with DNA and induces DNA binding-independent neurotoxicity.
    Friedman MJ; Wang CE; Li XJ; Li S
    J Biol Chem; 2008 Mar; 283(13):8283-90. PubMed ID: 18218637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurodegeneration. A glutamine-rich trail leads to transcription factors.
    Freiman RN; Tjian R
    Science; 2002 Jun; 296(5576):2149-50. PubMed ID: 12077389
    [No Abstract]   [Full Text] [Related]  

  • 40. Mechanisms of RNA-induced toxicity in CAG repeat disorders.
    Nalavade R; Griesche N; Ryan DP; Hildebrand S; Krauss S
    Cell Death Dis; 2013 Aug; 4(8):e752. PubMed ID: 23907466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.